Skip to content Skip to footer

PharmaShots Magazine-February-2026 Edition

Shots: AI is moving drug development from computation to clinical confidence, showing how it now guides target discovery, molecule design, patient stratification, and trial planning while turning fragmented biomedical data into decision-ready insight that reduces risk, cost, and failure rates. Trust, transparency, and regulation define AI’s real breakthrough, as the focus shifts beyond speed toward…

Read more

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2025 (Part 01) 

Shots:    Lilly leads with precision and purpose with 45 deals totaling $21.22B in 2025, focusing on platform-driven, science-led partnerships across oncology, gene therapy, RNA editing, and AI-enabled discovery while building durable innovation engines rather than chasing short-term wins  Strategic dealmaking over sheer volume is evident in partnerships like precision oncology with Scorpion Therapeutics and CNS delivery with Sangamo, structured to…

Read more